TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has shared an update.
Oncoinvent ASA has appointed Dr. Ramzi Amri as the new Chief Financial Officer, succeeding Tore Kvam. Dr. Amri brings extensive experience from Galapagos NV and McKinsey & Company, which is expected to bolster Oncoinvent’s strategic and financial leadership as it advances its clinical programs. This leadership change is anticipated to enhance the company’s operations and value creation for patients and shareholders.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using the alpha-emitting radionuclide radium-224. The company is actively conducting clinical trials to evaluate the safety and efficacy of Radspherin® and operates a manufacturing facility in Oslo. Oncoinvent is listed on the Oslo Stock Exchange.
Average Trading Volume: 86,823
Current Market Cap: NOK186.4M
See more data about BRRGF stock on TipRanks’ Stock Analysis page.